반응식
[Cl:1][C:2]1[CH:27]=[CH:26][CH:25]=[CH:24][C:3]=1[CH2:4][C:5]1[C:12](=[O:13])[N:8]2[CH2:9][CH2:10][CH2:11][N:7]2[C:6]=1[C:14]1[CH:19]=[CH:18][N:17]=[C:16](S(C)(=O)=O)[N:15]=1.N[CH:29]1[CH2:34][CH2:33][CH2:32][CH2:31][O:30]1.C[N:36]1C(=O)CCC1>CO>[Cl:1][C:2]1[CH:27]=[CH:26][CH:25]=[CH:24][C:3]=1[CH2:4][C:5]1[C:12](=[O:13])[N:8]2[CH2:9][CH2:10][CH2:11][N:7]2[C:6]=1[C:14]1[CH:19]=[CH:18][N:17]=[C:16]([NH:36][CH:33]2[CH2:32][CH2:31][O:30][CH2:29][CH2:34]2)[N:15]=1참가 물질
5
반응물 3
생성물 1
시약·촉매·용매 1
반응 조건
- 온도
- 90 °C
실험 절차
To a solution of 2-(2-chloro-benzyl)-3-(2-methanesulfonyl-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one, 8, (0.10, 0.26 mmol) in NMP (2 mL) is added amino tetrahydropyran (0.09 mL, 0.78 mmol). After stirring 1.5 hours at 90° C., the reaction mixture is diluted with methanol (to 5 mL) and is purified by reversed phase liquid chromatography (CH3CN/water/1% TFA) to afford 44 mg (40%) of the desired product. 1H NMR (300 MHz, CDCl3) δ 8.30 (d, J=5.1 Hz, 1H), 7.39-7.12 (m, 4H), 6.57 (d, J=5.1 Hz, 1H), 4.10-3.94 (m, 9H), 3.60-3.48 (m, 2H), 2.80-2.68 (m, 2H), 2.95-1.95 (m, 2H), 1.65-1.50 (m, 2H); ESI− MS: m/z (rel intensity) 426.0 (100, M+−H).
후처리
- customis purified by reversed phase liquid chromatography (CH3CN/water/1% TFA)
출처 및 근거
- ORD 기록
- ord-fe7085b51a444e5ba2eeca0845c5ceb5
- 출처 데이터셋
- uspto-grants-2009_01
- 특허 번호
- US07482356B2
연결된 노트
불러오는 중…